Search results for " antibody"

showing 10 items of 815 documents

PREVALENCE OF ANTIBODIES ANTI-BARTONELLA HENSELAEIN WESTERN SICILY: CHILDREN, BLOOD DONORS, AND CATS

2011

To evaluate seroprevalence of B. henselae infection both in Sicilian children and healthy blood donors. Furthermore, circulation of Bartonella in the natural reservoir was also studied. Two hundred forty-three children, living in Sicily (Palermo), affected by various diseases, without clinical features suggesting B. henselae infection, together with 122 healthy blood donors were serologically investigated for IgG and IgM antibodies by indirect fluorescent antibody test (IFAT). One hundred twenty stray and 62 pet cats were also analyzed only for IgG. Among children 25.1% had IgG antibodies to B. henselae; 18.5% showed a titer 1:64, 2.4% 1:128, 2.4% 1:256, 0.8% 1:512, 0.4% 1:1024, and 0.4% 1:…

AdultMaleBartonellaAdolescentClinical BiochemistryImmunologyBlood DonorsYoung AdultmedicineAnimalsHumansImmunology and AllergySeroprevalenceChildFluorescent Antibody Technique IndirectSicilyDirect fluorescent antibodyAntigens BacterialBartonella henselaeBartonella henselaeCATSbiologyInfantCat-scratch diseaseMiddle Agedbiology.organism_classificationmedicine.diseaseAntibodies BacterialVirologyMedical Laboratory TechnologyTiterImmunoglobulin MChild PreschoolImmunoglobulin GImmunologyCatsbiology.proteinFemaleAntibodyJournal of Immunoassay and Immunochemistry
researchProduct

Screening for Autoantibodies to Tissue Transglutaminase Reveals a Low Prevalence of Celiac Disease in Blood Donors with Cryptogenic Hypertransaminase…

2001

Patients with chronic cryptogenic hypertransaminasemia are at high risk of developing celiac disease (CD). In fact, among the various serological disorders, CD patients at onset frequently present hypertransaminasemia. In this study, we evaluated usefulness and reliability of the new test for antitissue transglutaminase (tTG) in screening for CD as well as in estimating the prevalence of CD in a population of blood donors presenting unexplained hypertransaminasemia at donation. Controls were 180 consecutive healthy donors without hypertransaminasemia and 20 CD patients with known antiendomysial antibody (EmA) positivity. Out of 22,204 blood donors over a period of 2 years, we found 258 subj…

AdultMaleBlood donormedicine.medical_specialtyTissue transglutaminasePopulationE2F6 Transcription FactorBlood DonorsEnzyme-Linked Immunosorbent AssaySensitivity and SpecificityGastroenterologyCoeliac diseaseSerologyIntestinal mucosaInternal medicineImmunopathologyBiopsyPrevalencemedicineHumansCeliac diseaseIntestinal MucosaFluorescent Antibody Technique IndirecteducationTransaminasesAutoantibodieseducation.field_of_studyTransglutaminasesbiologymedicine.diagnostic_testbusiness.industryGastroenterologyAutoantibodyReproducibility of ResultsMiddle Agedmedicine.diseaseTransglutaminaseRepressor ProteinsImmunologybiology.proteinFemalebusinessTranscription FactorsDigestion
researchProduct

Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1.

1997

Abstract Background/Aim: Anti-neutrophil cytoplasmic antibodies (ANCA) are a group of autoantibodies first associated with Wegener's granulomatosis and microscopic polyangiitis. The signifiance of ANCA in autoimmune hepatitis remains uncertain; the nature of the antigen or antigens has not been defined yet. The purpose of this study was to identify the target antigen of ANCA in patients with autoimmune hepatitis. Method/Results: Sera from 32 type-1 autoimmune hepatitis patients were used in the present study. ANCA were detected in 24 of 32 sera (75%). A diffuse cytoplasmic staining pattern (C-ANCA) was detected in 14 patients; the P-ANCA pattern was observed in 10 patients. An extract of hu…

AdultMaleBlotting WesternEnzyme-Linked Immunosorbent AssayAutoimmune hepatitisTropomyosinMyosinsAntibodies Antineutrophil CytoplasmicAutoimmune DiseasesHepatitisAntigenmedicineHumanscardiovascular diseasesAntigensFluorescent Antibody Technique IndirectAnti-neutrophil cytoplasmic antibodyAgedAutoimmune diseaseHepatitisAged 80 and overHepatologybiologyAutoantibodyActomyosinBlood ProteinsMiddle Agedmedicine.diseaseActinsMolecular WeightImmunologybiology.proteinFemaleAntibodyMicroscopic polyangiitisJournal of hepatology
researchProduct

The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3…

2008

Activating mutations of FLT3 are found in approximately one-third of acute myeloid leukemia (AML)-cases and are considered to represent an attractive therapeutic target. In this study, we report that the hydroxystyryl-acrylonitrile compound LS104 inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells in vitro. Immunoblot and phosphoprotein-FACS analysis demonstrated inhibiton of phosphorylation of FLT3-ITD and of its downstream targets. In pharmacokinetic studies, a rapid and dose dependent cellular uptake of LS104 lasting up to 11h could be demonstrated. Combination of LS104 with chemotherapeutic agents markedly enhanced cytotoxic effects. Recently, a…

AdultMaleCancer ResearchDaunorubicinmedicine.drug_classBlotting WesternFluorescent Antibody TechniqueApoptosisPharmacologyReceptor tyrosine kinaseTyrosine-kinase inhibitorStyrenesColony-Forming Units AssayMiceBone Marrowhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineTumor Cells CulturedCD135AnimalsHumansPoint MutationTissue DistributionAgedCell ProliferationAged 80 and overbiologyAcrylonitrileDaunorubicinCytarabineMyeloid leukemiaCell DifferentiationHematologyMiddle Agedmedicine.diseaseLeukemiaLeukemia Myeloid AcuteOncologyfms-Like Tyrosine Kinase 3Fms-Like Tyrosine Kinase 3Cytarabinebiology.proteinCancer researchDrug Therapy CombinationFemalemedicine.drugSignal TransductionLeukemia research
researchProduct

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1997

Peptides derived from melanocyte differentiation antigens have been identified as targets for MHC class I-restricted cytolytic T lymphocytes (CTLs) in human melanoma Regression of antigen-expressing tumors as well as selection of antigen-loss variants in the presence of antigen-specific CTLs have previously been reported. In the present study, we determined the expression of the melanocyte differentiation antigens Melan A/MART-1 and tyrosinase by mRNA analysis and by immunohistochemical staining with the monoclonal antibodies (MAbs) A103 and T311. Co-expression of Melan A/MART-1 and tyrosinase was detected by both methods in 18/20 melanomas tested. However, immunohistochemistry provided add…

AdultMaleCancer ResearchSkin Neoplasmsmedicine.drug_classBiopsyGenes MHC Class I10050 Institute of Pharmacology and Toxicology610 Medicine & healthMonoclonal antibodyPolymerase Chain ReactionMART-1 AntigenMelanocyte differentiationAntigenAntigens NeoplasmMHC class IHLA-A2 AntigenmedicineHumans1306 Cancer ResearchRNA MessengerMelanomaAgedDNA PrimersAged 80 and overbiologyMonophenol MonooxygenaseLiver NeoplasmsMiddle AgedImmunohistochemistryNeoplasm ProteinsCytolysisCTL*OncologyTumor progressionLymphatic MetastasisImmunologyCancer researchbiology.proteinImmunohistochemistry570 Life sciences; biologyFemale2730 Oncology
researchProduct

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.

2004

Contains fulltext : 57114.pdf (Publisher’s version ) (Closed access) Chimeric monoclonal antibody G250 (WX-G250) binds to a cell surface antigen found on >90% of renal cell carcinoma (RCC). A multicentre phase II study was performed to evaluate the safety and efficacy of WX-G250 in metastatic RCC (mRCC) patients. In all, 36 patients with mRCC were included. WX-G250 was given weekly by intravenous infusion for 12 weeks. Patients with stable disease (SD) or response were eligible to receive additional treatment for 8 weeks. None of the 36 enrolled patients experienced any drug-related grade III or IV toxicity. Only three patients had grade II toxicity possibly related to the study medication.…

AdultMaleCancer Researchmedicine.medical_specialtyrenal cell carcinomaRecombinant Fusion ProteinsPhases of clinical researchAntineoplastic AgentsGastroenterologyClinicalMonoclonal antibody G250Renal cell carcinomaInternal medicinemedicineCarcinomaHumansProspective StudiesCarcinoma Renal CellAgedbusiness.industryGirentuximabAntibodies MonoclonalImmunotherapy gene therapy and transplantation [UMCN 1.4]CA-IXMiddle Agedmedicine.diseaseKidney NeoplasmsSurgeryClinical trialTreatment OutcomeOncologymonoclonal antibodyAntigens SurfaceFemaleimmunotherapybusinessWX-G250Progressive diseasemedicine.drugKidney disease
researchProduct

Antibodies to Cathepsin G in Crohn's disease

1992

. Antibodies directed against antigens in human neutrophils have proved to be of great diagnostic value in certain systemic vasculitides. Recent reports have focused the attention on these antigens as targets of antibodies in sera of patients with inflammatory bowel disease. We investigated the sera drawn from 60 patients suffering from biopsy proven Crohn's disease and 15 patients with active ulcerative colitis. Using sensitive enzyme-linked immunosorbent assays with purified antigens and Western blotting the following antibodies could be demonstrated: cathepsin G (cat-G) antibodies IgG 38.3%, IgM 13.3%, IgA 23.3% and antibodies against human leucocyte elastase (HLE) IgG, IgA, IgM 3.3%. Lo…

AdultMaleCathepsin GAdolescentAnti-nuclear antibodyNeutrophilsBlotting WesternClinical BiochemistryImmunoglobulinsEnzyme-Linked Immunosorbent AssayCathepsin GBiochemistryInflammatory bowel diseasechemistry.chemical_compoundCrohn DiseaseAntigenProteinase 3HumansMedicineChildAgedAutoantibodiesCrohn's diseasePancreatic Elastasebiologybusiness.industrySerine EndopeptidasesGeneral MedicineMiddle Agedmedicine.diseaseCathepsinsUlcerative colitischemistryImmunologybiology.proteinElectrophoresis Polyacrylamide GelFemaleAntibodybusinessEuropean Journal of Clinical Investigation
researchProduct

Qualitative assessment of SARS-CoV-2-specific antibody avidity by lateral flow immunochromatographic IgG/IgM antibody assay.

2020

Abstract Knowledge of the precise timing of SARS‐CoV‐2 infection may be of clinical and epidemiological relevance. The presence of low‐avidity IgGs has conventionally been considered an indicator of recent infection. Here, we carried out qualitative assessment of SARS‐CoV‐2‐specific antibody avidity using an urea (6M) dissociation test performed on a lateral flow immunochromatographic IgG/IgM device. We included a total of 76 serum specimens collected from 57 COVID‐19 patients, of which 39 tested positive for both IgG and IgM and 37 only for IgG. Sera losing IgG reactivity after urea treatment (n = 28) were drawn significantly earlier (P = .04) after onset of symptoms than those which prese…

AdultMaleCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Short CommunicationAntibody AffinityShort CommunicationsAntibodies ViralImmunoglobulin GSARS‐CoV‐2COVID-19 Serological Testing03 medical and health sciences0302 clinical medicineavidityVirologyurea dissociationMedicineHumansantibodiesIn patientAvidity030212 general & internal medicineQualitative ResearchAgedAged 80 and overImmunoassayCovid‐19medicine.diagnostic_testbiologybusiness.industrySARS-CoV-2COVID-19Middle AgedVirologySpecific antibodyInfectious DiseasesImmunoglobulin MImmunoglobulin MImmunoassayImmunoglobulin GImmunologybiology.protein030211 gastroenterology & hepatologyFemaleAntibodybusinessJournal of medical virology
researchProduct

Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis.

2019

Background: Daclizumab is a monoclonal antibody that binds the high-affinity interleukin-2 receptor and was approved for the treatment of relapsing multiple sclerosis. Due to severe inflammatory brain disorders, the approval was suspended in March 2018. Objective and Methods: This retrospective cohort study summarizes clinical, laboratory, radiological, and histological findings of seven patients who developed meningo-/encephalitis after daclizumab therapy. Results: Patients presented with encephalitis and/or meningitis and suffered from systemic symptoms such as fever (5/7), exanthema (5/7), or gastrointestinal symptoms (4/7). Secondary autoimmune diseases developed. Blood analysis reveale…

AdultMaleDaclizumabMultiple Sclerosismedicine.drug_classMonoclonal antibodyAutoimmune Diseases03 medical and health sciences0302 clinical medicineDaclizumabmedicineHumansLymphocytes030304 developmental biologyRetrospective Studies0303 health sciencesbusiness.industryMultiple sclerosisMeningoencephalitisAntibodies MonoclonalBrainMiddle Agedmedicine.disease3. Good healthNeurologyImmunologyEncephalitisFemaleNeurology (clinical)business030217 neurology & neurosurgeryEncephalitisImmunosuppressive Agentsmedicine.drugMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Analysis of seroprevalence against Coxiella burnetii in a sample of farm workers in Western Sicily

2016

Introduction and objective. Little is known about the development of chronic Q fever caused by Coxiella burnetii in occupational risk groups and in the general population in Italy, as well as in many countries in the world. The aim of this study was to highlight the presence of the infection in a sample of workers operating outdoors (but not directly in contact with animals), in three provinces of western Sicily, in order to detect the human seroprevalence and compare the obtained data with those found in animals raised in the same territory. Materials and methods. The study included 126 generic seasonal agricultural workers (labourers), 84 male and 42 female; none of whom were aware of any…

AdultMaleFarmersSheepSettore MED/44 - Medicina Del LavoroCattle DiseasesSheep DiseasesMiddle AgedYoung AdultCoxiella burnetiiSeroepidemiologic StudiesPrevalenceQ fever environmental exposure Coxiella burnetiiAnimalsHumansCattleFemaleFluorescent Antibody Technique IndirectQ FeverSicily
researchProduct